Universal Vision Biotechnology Co Ltd (3218) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Universal Vision Biotechnology Co Ltd (3218) has a cash flow conversion efficiency ratio of 0.125x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$521.08 Million ≈ $16.42 Million USD) by net assets (NT$4.16 Billion ≈ $131.04 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Universal Vision Biotechnology Co Ltd to measure how much of total assets are equity-financed.
Universal Vision Biotechnology Co Ltd - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Universal Vision Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 3218 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Universal Vision Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Universal Vision Biotechnology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rapac Communication & Infrastructure Ltd
TA:RPAC
|
-0.017x |
|
Hellenic Exchanges - Athens Stock Exchange SA
AT:EXAE
|
0.162x |
|
Hua Jung Components Co Ltd
TWO:5328
|
-0.240x |
|
Pitti Engineering Limited
NSE:PITTIENG
|
0.097x |
|
Bumble Inc
NASDAQ:BMBL
|
0.105x |
|
Kap Industrial Holdings Ltd
JSE:KAP
|
0.023x |
|
Panoro Energy ASA
F:1PZ
|
0.139x |
|
CMC Magnetics Corp
TW:2323
|
0.000x |
Annual Cash Flow Conversion Efficiency for Universal Vision Biotechnology Co Ltd (2003–2025)
The table below shows the annual cash flow conversion efficiency of Universal Vision Biotechnology Co Ltd from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see 3218 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$4.16 Billion ≈ $131.04 Million |
NT$1.67 Billion ≈ $52.50 Million |
0.401x | -10.00% |
| 2024-12-31 | NT$3.76 Billion ≈ $118.33 Million |
NT$1.67 Billion ≈ $52.68 Million |
0.445x | -4.20% |
| 2023-12-31 | NT$3.34 Billion ≈ $105.32 Million |
NT$1.55 Billion ≈ $48.95 Million |
0.465x | +3.68% |
| 2022-12-31 | NT$2.83 Billion ≈ $89.14 Million |
NT$1.27 Billion ≈ $39.95 Million |
0.448x | +14.47% |
| 2021-12-31 | NT$2.33 Billion ≈ $73.36 Million |
NT$911.77 Million ≈ $28.73 Million |
0.392x | -3.44% |
| 2020-12-31 | NT$2.04 Billion ≈ $64.25 Million |
NT$827.08 Million ≈ $26.06 Million |
0.406x | +64.02% |
| 2019-12-31 | NT$1.70 Billion ≈ $53.41 Million |
NT$419.18 Million ≈ $13.21 Million |
0.247x | +45.68% |
| 2018-12-31 | NT$1.61 Billion ≈ $50.69 Million |
NT$273.07 Million ≈ $8.60 Million |
0.170x | +13.59% |
| 2017-12-31 | NT$1.58 Billion ≈ $49.86 Million |
NT$236.48 Million ≈ $7.45 Million |
0.149x | -32.07% |
| 2016-12-31 | NT$1.16 Billion ≈ $36.54 Million |
NT$255.13 Million ≈ $8.04 Million |
0.220x | +37.79% |
| 2015-12-31 | NT$1.15 Billion ≈ $36.22 Million |
NT$183.54 Million ≈ $5.78 Million |
0.160x | -17.91% |
| 2014-12-31 | NT$1.14 Billion ≈ $35.94 Million |
NT$221.81 Million ≈ $6.99 Million |
0.194x | +16.31% |
| 2013-12-31 | NT$1.10 Billion ≈ $34.61 Million |
NT$183.66 Million ≈ $5.79 Million |
0.167x | +144.36% |
| 2011-12-31 | NT$1.14 Billion ≈ $35.88 Million |
NT$77.91 Million ≈ $2.45 Million |
0.068x | -46.06% |
| 2010-12-31 | NT$663.76 Million ≈ $20.91 Million |
NT$84.19 Million ≈ $2.65 Million |
0.127x | -26.41% |
| 2008-12-31 | NT$539.22 Million ≈ $16.99 Million |
NT$92.94 Million ≈ $2.93 Million |
0.172x | -0.41% |
| 2006-12-31 | NT$546.91 Million ≈ $17.23 Million |
NT$94.66 Million ≈ $2.98 Million |
0.173x | -57.01% |
| 2004-12-31 | NT$305.87 Million ≈ $9.64 Million |
NT$123.14 Million ≈ $3.88 Million |
0.403x | +71.74% |
| 2003-12-31 | NT$235.39 Million ≈ $7.42 Million |
NT$55.18 Million ≈ $1.74 Million |
0.234x | -- |
About Universal Vision Biotechnology Co Ltd
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. The company offers optical instruments, eyeglasses, contact lenses, and eyeglass accessories. It is also involved in eyeglasses optometry and dispensing services and leasing of medical devices. In addition, the company offers hospital management, optometric, and technical consultancy analysis, as we… Read more